EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ChanLingGao alleviates intestinal mucosal barrier damage and suppresses the onset and progression of Colorectal cancer in AOM/DSS murine model

Ting-Ting Tian, Guo Chen, Kai Sun, Xiao-Yi Wang, Yang Liu, Fei-Qing Wang, Bing Yang, Jian Liu, Jing-Yan Han, Dong-Xin Tang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Ting-Ting Tian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Research Department, First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China. Hauptthemen laut MEDLINE: Intestinal Mucosa, Colorectal Neoplasms, Gastrointestinal Microbiome, Disease Models, Animal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Bureau, Guiyang Municipal Government, Department of Education of Guizhou Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The occurrence of Colorectal Cancer (CRC) is influenced by various factors, including host susceptibility, immune imbalance, and environmental triggers. Numerous studies have underscored the critical role of chronic intestinal inflammation and dysbiosis in the development of CRC. Traditional Chinese Medicine (TCM) holds unique advantages in regulating the intricate process of and comprehensive treatment for systemic disease. Previous investigations by our team have confirmed the anti-cancer properties of the TCM compound ChanLingGao (CLG), including inhibiting cancer cell migration, and alleviating bone cancer pain. However, the mechanisms underlying its efficacy in alleviating chronic intestinal inflammation, modulating the gut microbiota, and protecting the intestinal mucosal barrier remain largely unknown. PURPOSE: This study aims to explore the inhibitory effects of CLG on CRC tumors in mice and its potential mechanisms. METHODS: A chronic inflammation-related CRC mouse model was established using AOM/DSS. The study examined the mechanisms of intestinal inflammation and tumor cell proliferation through intestinal histological morphology. High-throughput sequencing was employed to analyze changes in gut microbiota diversity and intestinal mucosal barrier integrity in CRC mice. Based on network pharmacology target prediction and Wnt/β-catenin signaling pathway analysis, the study analyzed and discussed the potential mechanisms of CLG on CRC. RESULTS: CLG significantly ameliorated weight loss and increased survival rates in CRC mice, while suppressing tumor growth in the intestinal tract. Post-CLG treatment improved intestinal inflammation in CRC mice, with a significant reduction in inflammatory factors IL-6, IL-23 and LCN2, and inhibition of tumor cell proliferation markers Proliferating Cell Nuclear Antigen (PCNA), Recombinant Ki-67 Protein (Ki-67), and CCND1. 16sV3-V4 region microbiota sequencing results indicated that CLG improved dysbiosis, and significantly increased the abundance of Akkermansia bacteria, further promoting the expression of MUC-2 protein and mucin secretion. Additionally, CLG prevented the disruption of intestinal epithelial cell junction proteins Occludin, Claudin-1, ZO-1, and E-cadherin, restored the number of goblet cells, and preserved the integrity of the intestinal mucosal barrier. Further experiments suggested that CLG inhibited abnormal activation of the Wnt/β-catenin pathway, and its potential mechanism in maintaining mucosal barrier integrity might be related to blocking Wnt/β-catenin pathway. CONCLUSIONS: This study demonstrates that CLG can inhibit CRC tumor growth by regulating the gut microbiota structure, reducing intestinal inflammation, improving intestinal mucosal barrier function, and inhibiting the complex process of cancer cell proliferation. This provides new clinical insights into the "membrane-oriented" treatment of CRC with CLG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal MucosaColorectal NeoplasmsGastrointestinal MicrobiomeDisease Models, AnimalDrugs, Chinese HerbalDextran SulfateAnimalsMiceWnt Signaling PathwayMaleMice, Inbred C57BLAzoxymethaneHumansCell ProliferationDisease Progression

Stichwörter der Autor:innen

ChanLingGaoColorectal CancerGut microbiotaIntestinal Mucosal Barrier

Substanzen

Drugs, Chinese HerbalDextran SulfateAzoxymethane

Autor:innen und Institutionen

  • Scientific Research Department, First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China.
  • Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
  • Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China. Electronic address: hanjingyan@bjmu.edu.cn.
  • Scientific Research Department, First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China. Electronic address: tangdongxin@sina.com.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Bureau, Guiyang Municipal Government
  • Department of Education of Guizhou Province

Zitieren

APA

Tian, T. T., Chen, G., Sun, K., Wang, X. Y., Liu, Y., Wang, F. Q., Yang, B., Liu, J., Han, J. Y., & Tang, D. X. (2024). ChanLingGao alleviates intestinal mucosal barrier damage and suppresses the onset and progression of Colorectal cancer in AOM/DSS murine model. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113193

Vancouver

Tian TT, Chen G, Sun K, Wang XY, Liu Y, Wang FQ, et al. ChanLingGao alleviates intestinal mucosal barrier damage and suppresses the onset and progression of Colorectal cancer in AOM/DSS murine model. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113193

BibTeX
@article{Tian2024,
  author = {Tian, Ting-Ting and Chen, Guo and Sun, Kai and Wang, Xiao-Yi and Liu, Yang and Wang, Fei-Qing and Yang, Bing and Liu, Jian and Han, Jing-Yan and Tang, Dong-Xin},
  title = {ChanLingGao alleviates intestinal mucosal barrier damage and suppresses the onset and progression of Colorectal cancer in AOM/DSS murine model},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113193}
}
Kostenlos starten →